Clinical trials: Refractory Ulcerative Colitis
Ulcerative Colitis
Long-Term Safety Of PF-00547659 In Ulcerative Colitis
Subjects with Ulcerative Colitis who have completed an induction study with PF-00547659 will receive an additional 144 weeks of open-label treatment to evaluate the long-term safety of the drug.
- Trial name
- TURANDOT II (NCT01771809)
- Testing
- 75mg SHP647 (PF-00547659), 225mg SHP647 (PF-00547659)
- Where
- 99 sites in United States, Australia and 19 more
- Volunteers
- 330 people
- Sponsor
- Shire
Severe Ulcerative Colitis
Ulcerative Colitis Study: Study of Visilizumab in Patients With Severe Ulcerative Colitis
The purpose of this study is to evaluate the safety and tolerability of visilizumab in patients with severe ulcerative colitis that has failed to respond to steroid therapy.
- Trial name
- NCT00267306
- Testing
- Visilizumab
- Where
- 11 sites in United States
- Volunteers
- 144 people
- Sponsor
- Facet Biotech
Inflammatory Bowel Diseases, Crohn's Disease
Thalidomide in Pediatric Inflammatory Bowel Diseases.
Several open-label studies reported thalidomide efficacy in inducing clinical remission and steroid tapering in refractory Inflammatory Bowel diseases (IBD), both in adults and in children.
- Conditions
- Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis
- Trial name
- TALIBDP (NCT00720538)
- Testing
- Thalidomide
- Where
- 7 sites in Italy
- Volunteers
- 84 people
- Sponsor
- IRCCS Burlo Garofolo
Ulcerative Colitis
A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis
The purpose of this study is to compare the efficacy of visilizumab to placebo in subjects with intravenous steroid-refractory ulcerative colitis.
- Trial name
- NCT00279422
- Testing
- visilizumab
- Where
- 70 sites in United States, Australia and 12 more
- Volunteers
- 127 people
- Sponsor
- Facet Biotech
Ulcerative Colitis
A Study to Investigate the Safety and Efficacy of LT-02 in Patients With Mesalamine Refractory Ulcerative Colitis (UC)
The purpose of this study is to determine whether Phosphatidylcholine (LT-02) add on treatment is effective and safe for the induction of remission in ulcerative colitis patients refractory to standard treatment with mesalamine
- Trial name
- PROTECT-3 (NCT02849951)
- Testing
- LT-02
- Where
- 45 sites in United States
- Volunteers
- 25 people
- Sponsor
- Prometheus Laboratories
Crohn's Disease (CD), Ulcerative Colitis (UC)
Upadacitinib for Refractory IBD in Asian Children and Elderly: Age-Stratified Analysis
This single-center, retrospective study aims to evaluate the effectiveness and safety of upadacitinib (UPA) in Asian pediatric patients with refractory Crohn's disease (CD) and elderly patients with refractory ulcerative colitis…
- Conditions
- Crohn's Disease (CD), Ulcerative Colitis (UC), Refractory Crohn's Disease, Refractory Ulcerative Colitis
- Trial name
- UPA-AGE (NCT06922331)
- Testing
- Upadacitinib
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Ulcerative Colitis
Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study
The purpose of this study is to compare the efficacy, safety, pharmacokinetics, and immunogenicity in subjects retreated with visilizumab or placebo after a response in a prior visilizumab study.
- Trial name
- NCT00279435
- Testing
- visilizumab
- Where
- 39 sites in United States, Australia and 13 more
- Volunteers
- 25 people
- Sponsor
- Facet Biotech
Ulcerative Colitis
Retrospective Observational Comparison Study Between Ustekinumab and Tofacitinib as Third Line Therapy in a Multicenter Cohort of Patients With Refractory Ulcerative Colitis.
Ulcerative colitis (UC) is a chronic remitting and relapsing inflammatory bowel disease. The pathogenesis is multifactorial, involving genetic predisposition, epithelial barrier defects, dysregulated immune responses, and…
- Trial name
- NCT05728008
- Testing
- Ustekinumab, Tofacitinib
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- IRCCS San Raffaele
Ulcerative Colitis
Efficacy & Safety in Moderately Active Refractory Ulcerative Colitis Patients
This study is designed as a proof of concept of KRP203 for induction of remission in ulcerative colitis (UC). The purpose of this study is to evaluate clinical benefit of KRP203 in subjects with moderately active refractory…
- Trial name
- NCT01375179
- Testing
- KRP203
- Where
- 14 sites in Belgium, Germany and 4 more
- Volunteers
- 27 people
- Sponsor
- Novartis Pharmaceuticals
Colitis, Ulcerative
Comparison of Medical RESCUE Strategies for Patients With Steroid-refractory Acute Severe Ulcerative Colitis
This study aims to examine patients with acute severe UC who are refractory to intravenous corticosteroids and determine whether a strategy of using upadacitinib first followed by infliximab in upadacitinib non-responders is…
- Trial name
- RESCUE UC (NCT06660693)
- Testing
- Upadacitinib Oral Product
- Where
- Canada
- Volunteers
- 134 people
- Sponsor
- McMaster University
Ulcerative Colitis
CT to Assess the Efficacy and Safety of Adding GMA to Infliximab in Paediatric Patients With Steroid-refractory Ulcerative Colitis
The primary endpoint will be evaluated through the following variables: PUCAI score, IFX levels, and steroid treatment. Clinical response to IFX will be evaluated through the PUCAI score.
- Trial name
- NCT05430412
- Testing
- Adacolumn
- Where
- 10 sites in Portugal, Spain
- Volunteers
- 15 people
- Sponsor
- Adacyte Therapeutics SL
Ulcerative Colitis
Research Study in Patients With Severe Ulcerative Colitis
The purpose of the study is to evaluate an intravenous (by injection) investigational medication to treat severe ulcerative colitis refractory to steroid therapy.
- Trial name
- NCT00032305
- Testing
- Visilizumab
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Facet Biotech
Ulcerative Colitis, Inflammatory Bowel Diseases
Study of ExoFlo for the Treatment of Medically Refractory Ulcerative Colitis
Protocol Summary Title: A Phase I study of ExoFlo, an ex vivo culture-expanded adult allogeneic bone marrow mesenchymal stem cell derived extracellular vesicle isolate product, for the treatment of medically refractory ulcerative…
- Trial name
- NCT05176366
- Testing
- ExoFlo
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Direct Biologics, LLC
Ulcerative Colitis
ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis
This Phase IIa study is an 8-week, double-blind, placebo-controlled, randomized study aiming at evaluating the safety and the efficacy of ABX464 given once a day (o.d) at 50 mg in subjects with moderate to severe Active…
- Trial name
- NCT03093259
- Testing
- ABX464
- Where
- 19 sites in Austria, Belgium and 6 more
- Volunteers
- 32 people
- Sponsor
- Abivax S.A.
Ulcerative Colitis
Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Ulcerative Colitis (UC)
The purpose of this study is to determine the safety and efficacy of using remestemcel-L, an ex vivo culture-expanded adult allogeneic bone marrow derived mesenchymal stem cell product (MSCs) delivered by targeted endoscopic…
- Trial name
- UC (NCT04543994)
- Testing
- Remestemcel-L
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- The Cleveland Clinic
Ulcerative Colitis
Fecal Transplantation Using a Diet for Donor and Recipient in Refractory Colitis
Changing the microbiota has become the most intriguing target for intervention in inflammatory bowel disease (IBD). Dietary therapy is successful in mild to moderate Crohn's disease and may be effective in mild to moderate…
- Trial name
- NCT02734589
- Testing
- Fecal transplantation, Unique novel Diet for UC and Unique novel Diet for the donor + FMT, Unique novel Diet for UC
- Where
- 5 sites in France, Israel and 1 more
- Volunteers
- 54 people
- Sponsor
- Wolfson Medical Center
Ulcerative Colitis
The Efficacy of Hyperbaric Oxygen-assisted Treatment for ASUC and Refractory IBD
The Department of Gastroenterology plans to conduct a randomized controlled study on the efficacy analysis of hyperbaric oxygen-assisted treatment for acute severe ulcerative colitis and refractory inflammatory bowel disease.
- Trial name
- NCT07257588
- Testing
- Administration of methylprednisolone sodium succinate, Hyperbaric Oxygen Therapy
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Xijing Hospital of Digestive Diseases
Ulcerative Colitis
Phosphatidylcholine (LT-02) for Induction of Remission in Ulcerative Colitis
The purpose of this study is to compare two different dosing regimens of phosphatidylcholine versus placebo for the induction of remission in ulcerative colitis patients non-responsive to standard mesalamine treatment.
- Trial name
- PROTECT-1 (NCT02142725)
- Testing
- LT-02
- Where
- Germany
- Volunteers
- 468 people
- Sponsor
- Dr. Falk Pharma GmbH
Crohn Disease, Ulcerative Colitis
Clinical Study of Targeting CD7 CAR-T Cells in the Treatment of Autoimmune Diseases
A Clinical Study on the Safety and Effectiveness of Targeting CD7 Chimeric Antigen Receptor T Cells in the Treatment of Autoimmune Diseases
- Conditions
- Crohn Disease, Ulcerative Colitis, Dermatomyositis, Still Disease
- Trial name
- NCT05239702
- Testing
- CD7 CAR T-cells
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Zhejiang University
Colitis, Ulcerative
The Efficacy and Safety of Cobitolimod (Kappaproct®) in Chronic Active Treatment Refractory Ulcerative Colitis Patients
The purpose of this study is to determine if cobitolimod (former called Kappaproct®) is effective in the treatment of chronic active ulcerative colitis patients not responding to available therapy.
- Trial name
- COLLECT (NCT01493960)
- Testing
- Cobitolimod
- Where
- 37 sites in Czechia, France and 5 more
- Volunteers
- 131 people
- Sponsor
- InDex Pharmaceuticals